A Study of Nivolumab in Patients With Head and Neck Cancer.

Inclusion Criteria: * Diagnosis of Squamous Cell Carcinoma Head and Neck (SCCHN) patients progressing on or after platinum-based therapy. * Diagnosis of SCCHN has been confirmed by histology or cytology (either at initial diagnosis or any time later during the course of the disease) * Treatment decision to initiate a treatment with nivolumab for the first time for the treatment of SCCHN (according to the label approved in France) has already been taken Exclusion Criteria: * Patients previously treated with Nivolumab, Ipilimumab, or any other antibody or drug specifically targeting T-Cell Co stimulation or immune Checkpoint pathway. * Patients currently included in an interventional clinical trial for their SCCHN. Other protocol defined inclusion/exclusion criteria could apply